Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Geert Nygaard, Thomas Taapken, Uwe Staub

Premium

Epigenomics CEO Geert Nygaard has left the firm and Thomas Taapken has been appointed as sole member of the company's executive board, effective Oct. 1.

Taapken previously served as CFO at Epigenomics, a position he held since April 2011. He joined Epigenomics from Biotie Therapies in Finland, where he also served as CFO. He was appointed to this position in 2008, following a merger between Biotie Therapies and Elbion, where Taapken had been CFO since 2005. He has also held positions as an investment partner at Deutsche Venture Capital and Burrill & Company. Taapken also worked several years at Sanofi-Aventis.

Epigenomics has also promoted Uwe Staub, former senior vice president of research and development, to the position of COO.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more